Primary Endpoint. The primary endpoint is based on the mean reduction in total length of operative time. Operative time will be determined by the official recorded operative notes.
Primary Endpoint. The primary endpoint of this study is HDSS score reduction from a 3 or 4 at baseline to a 1 or 2 at 30 days post-treatment #2.
Primary Endpoint. IRRC-assessed XXX and PFS, and OS, in intermediate-/poor-risk subjects with previously untreated advanced or metastatic RCC
Primary Endpoint. The primary outcome measure will be the tolerability of the application of the stem cell recovery complex (SCR Complex™) and a botanical lipid based occlusive (Bio Cel™) as compared with standard of care following fractional RF treatments.
Primary Endpoint. The primary endpoint will be the responder rate for lip fullness on the LFS2, which is defined as the proportion of subjects who show ≥ 1-point improvement on the LFS2 compared to baseline assessment, at Day 30 after last treatment received.
Primary Endpoint. The primary endpoint will be the proportion of subjects who achieve wound closure by or at 12-weeks post treatment with MIRODERM.
Primary Endpoint. Objective Response Rate The primary endpoint, XXX, is described in the master protocol.
Primary Endpoint. To measure patient compliance towards the targeted interventions by using electronic log information, digital diaries and a specific questionary.
Primary Endpoint. Identifying factors and processes that may predict both interim and long-term patient resilience, their physical wellbeing and psychological outcomes of cancer and cancer treatment.
Primary Endpoint. The main goal of the prospective pilot study is to identify factors, processes and health care infrastructures that may predict at different points in time and in the long-term the patient's resilience to the physically and psychologically stressful their physical wellbeing and the psychological outcomes of the cancer event.
